Fiona Bor - Mereo BioPharma Head Property
| 0A9G Stock | 3.55 0.15 4.41% |
Executive
Fiona Bor is Head Property of Mereo BioPharma Group
| Address | One Cavendish Place, London, United Kingdom, W1G 0QF |
| Phone | 44 33 3023 7300 |
| Web | https://www.mereobiopharma.com |
Mereo BioPharma Management Efficiency
The company has return on total asset (ROA) of (0.3065) % which means that it has lost $0.3065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7364) %, meaning that it generated substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. Net Tangible Assets is likely to gain to about 45.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 406.3 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ulf Klostermann | Uniper SE | N/A | |
| Ekaterina Savelyev | World Chess PLC | N/A | |
| Sebastian Veit | Uniper SE | N/A | |
| Graham Crocker | Heavitree Brewery | 66 | |
| Niek Hollander | Uniper SE | N/A | |
| Carsten Poppinga | Uniper SE | N/A | |
| Stefan Jost | Uniper SE | N/A | |
| FCA FCA | Mulberry Group PLC | 75 | |
| Fabienne Twelemann | Uniper SE | N/A | |
| Klaus Schaeffer | Uniper SE | 57 | |
| Katherine LLB | Mulberry Group PLC | N/A | |
| Andrea Baldo | Mulberry Group PLC | 52 | |
| Nicola McLean | Heavitree Brewery | N/A | |
| Christopher Delbrck | Uniper SE | 58 | |
| Alex Panteleev | World Chess PLC | N/A | |
| David Brown | SURETRACK MON | N/A | |
| Nicolo Prien | Uniper SE | 58 | |
| Risto MSc | Uniper SE | 56 | |
| Andrew Winton | World Chess PLC | N/A | |
| Sascha Fehlemann | Uniper SE | 46 | |
| Richard ACA | London Security Plc | 61 | |
Management Performance
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.31 |
Mereo BioPharma Group Leadership Team
Elected by the shareholders, the Mereo BioPharma's board of directors comprises two types of representatives: Mereo BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo BioPharma's management team and ensure that shareholders' interests are well served. Mereo BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine CPA, Chief Officer | ||
| Bo Kara, Senior CMC | ||
| Fiona Bor, Head Property | ||
| Charles Sermon, General CoFounder | ||
| MBBS MD, CoFounder Strategy | ||
| John Lewicki, Chief Officer | ||
| Jackie Parkin, Therapy Endocrinology | ||
| Alexandra HughesWilson, Chief Planning | ||
| John MBA, CoFounder Officer | ||
| Denise ScotsKnight, CEO CoFounder | ||
| Suba Krishnan, Senior Development | ||
| MBA MBA, CoFounder Officer |
Mereo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (38.07) % | ||||
| Current Valuation | 2.68 B | ||||
| Shares Owned By Insiders | 1.02 % | ||||
| Shares Owned By Institutions | 68.29 % | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 936 K | ||||
| EBITDA | (37.48 M) | ||||
| Net Income | (34.2 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.